
The Inspire Corporate Bond ETF primarily invests in high-quality debt securities issued by large American corporations that are selected for their inspiring and biblically aligned principles. This fund aims to mirror the performance outcomes of the Inspire Corporate Bond Index.
Is IBD's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Is the federal government's clash with Anthropic a warning sign for the entire artificial intelligence ecosystem? Tech strategist and Georgetown adjunct law professor Emily Benson breaks down the regulatory fallout for AI developers and investors.

The AI buildout's real bottleneck is the steel, copper, and chilled water surrounding the GPUs.

A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.

AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models